Tango Therapeutics has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $80,000,000.00 in Post-IPO Equity.
According to filings with the U.S. Securities and Exchange Commission, Tango Therapeutics is raising $80,000,000.00 in new funding. About Tango Therapeutics: Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
To learn more about Tango Therapeutics, visit http://www.tangotx.com/
Contact:
Barbara Weber, President and Chief Executive Officer
857-320-4900
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.